Adherence to omalizumab: A multicenter “real-world” study

Nicola Scichilone, Claudia Crimi, Alberto Noto, Raffaele Campisi, Giuseppe Valenti, Rossella Intravaia, Simona Strano, Corrado Pelaia, Maria Pia Foschino, Luisa Ricciardi, Vittorio Viviano, Maria Pia Foschino, Luisa Ricciardi, Nunzio Crimi

Research output: Contribution to journalArticlepeer-review

3 Citations (Scopus)


Background: Adherence to medications is crucial in patients with severe asthma in light of the negative clinical impact and costs of non-adherence. Adherence to omalizumab has not been well studied in real-world settings. The aim of this study was to assess adherence to omalizumab and evaluate treatment effectiveness in relation to adherence. Methods: This was a retrospective, observational, and multicenter real-world study. Omalizumab dose, timing of administration, and duration of treatment (<2 years; 2–4 years; > 4 years) were analyzed. Adherence was evaluated by examining rates of expected and missing doses. Good adherence (<10% of doses missed) and poor adherence (>10% doses missed) were determined. For effectiveness in relation to adherence of omalizumab we considered asthma exacerbations, hospitalizations, asthma control test (ACT), and Forced Expiratory Volume in 1 s (FEV1). Results: A total of 196 patients were evaluated, and 161 were suitable for data analyses. Good adherence was shown in 90.7% of patients and poor adherence in 9.3%. Considering adherence in relation to treatment duration: <2 years, 87.8% of patients were adherent (expected doses, 1186; missed doses, 53); 2–4 years, 85.9% were adherent (expected doses, 2985; missed doses, 127); >4 years, 100% were adherent (expected doses, 6120; missed doses, none). Indices of efficacy between pre- and post-treatment showed significant improvement (p < 0.001). The effectiveness indices between pre- and post-treatment, among adherent and non-adherent patients, ACT, and asthma exacerbations both showed significant differences (p = 0.043 and p = 0.049, respectively). Binomial logistic regression analysis showed that increasing age, better ACT score, and 14-day timing were significantly associated with increased adherence to therapy. Conclusions: High adherence to omalizumab was demonstrated in a real-world setting, which was associated with better outcomes and control of asthma.
Original languageEnglish
Pages (from-to)100103-
Number of pages0
Publication statusPublished - 2020

All Science Journal Classification (ASJC) codes

  • Immunology and Allergy
  • Immunology
  • Pulmonary and Respiratory Medicine

Fingerprint Dive into the research topics of 'Adherence to omalizumab: A multicenter “real-world” study'. Together they form a unique fingerprint.

Cite this